Medline ® Abstract for Reference 14
of 'Management of patients at high risk for breast and ovarian cancer'
A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices.
Geiger AM, Yu O, Herrinton LJ, Barlow WE, Harris EL, Rolnick S, Barton MB, Elmore JG, Fletcher SW
Arch Intern Med. 2005;165(5):516.
BACKGROUND: Findings from several studies suggest that bilateral prophylactic mastectomy reduces breast cancer incidence by 90% or more, but the studies used highly selected patients from referral centers, and the comparison groups were not population based. We studied the efficacy of bilateral prophylactic mastectomy in women with elevated breast cancer risk cared for in community practices.
METHODS: We conducted a retrospective case-cohort study of women aged 18 to 80 years with 1 or more breast cancer risk factors (family history of breast cancer, history of atypical hyperplasia, or>or =1 breast biopsies with benign findings). Using computerized data and medical records, we identified 276 women with bilateral prophylactic mastectomy and a stratified random sample of 196 women representing an underlying cohort of 666 800 women with elevated breast cancer risk without prophylactic mastectomy, and then we determined who developed breast cancer.
RESULTS: Breast cancer developed in 1woman (0.4%) after bilateral prophylactic mastectomy vs 26 800 women (4.0%) without prophylactic mastectomy. Stratifying by birth year, the hazard ratio for breast cancer occurrence after bilateral prophylactic mastectomy was 0.005 (95% confidence interval, 0.001-0.044). No woman with bilateral prophylactic mastectomy died of breast cancer vs a calculated 0.2% of women without prophylactic mastectomy.
CONCLUSIONS: Bilateral prophylactic mastectomy reduced breast cancer incidence in women at elevated risk for breast cancer cared for in community-based practices. However, the absolute risk of breast cancer incidence and death in women who did not undergo the procedure in these settings was relatively low.
Research and Evaluation Department, Southern California Permanente Medical Group, 100 S. Los Robles, Pasadena, CA 91101, USA. firstname.lastname@example.org